Live Analyst Rating Changes 1526 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Eliana Merle
BARC
Eliana Merle
Wall Street Analyst
★★★☆☆
#950
on 13Foresight · ranked by our own returns
51%
Success Rate
+33.4%
Average Return
23 of 45 calls profitable · +26.0% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 51% of Eliana Merle's ratings turned a profit when each position was held for 1 year — averaging +33.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

118 Buy 33 Hold 4 Sell
Eliana's Stock Coverage 37 ratings · 2026-06-21
Company Date Position Consensus Price Target 1-Yr Return
QURE
uniQure
Jun 18, 2026 BUY Strong Buy
+16.1% avg upside
29 analysts
$65.00
40.39% Upside
·
MBX
MBX Biosciences, Inc.
Jun 15, 2026 BUY Strong Buy
+53.4% avg upside
14 analysts
$70.00
62.69% Upside
+2.9%
BBIO
BridgeBio Pharma
Jun 05, 2026 BUY Strong Buy
+38.7% avg upside
34 analysts
$157.00
136.93% Upside
-0.3%
IVA
Inventiva
Jun 04, 2026 BUY Strong Buy
+350.1% avg upside
16 analysts
$18.00
404.30% Upside
-14.4%
TYRA
Tyra Bioscience
Jun 03, 2026 BUY Strong Buy
+57.9% avg upside
17 analysts
$59.00
108.42% Upside
+1.3%
MRNA
Moderna
Jun 03, 2026 HOLD Hold
+6.1% avg upside
38 analysts
$48.00
24.98% Downside
+30.4%
INSM
Insmed
May 28, 2026 BUY Strong Buy
+82.2% avg upside
36 analysts
$237.00
147.46% Upside
-9.2%
PTCT
PTC Therapeutics
May 27, 2026 BUY Buy
-1.5% avg upside
29 analysts
$120.00
51.94% Upside
+11.1%
BMRN
BioMarin Pharmaceutical
May 21, 2026 BUY Strong Buy
+72.8% avg upside
52 analysts
$105.00
91.99% Upside
+1.7%
GOSS
Gossamer Bio
May 18, 2026 SELL Buy
+4379.4% avg upside
17 analysts
$0.28
66.61% Upside
·
REGN
Regeneron
May 18, 2026 BUY Strong Buy
+26.9% avg upside
57 analysts
$917.00
50.26% Upside
-3.3%
RGNX
RegenXBio
May 15, 2026 BUY Strong Buy
+381.4% avg upside
22 analysts
$12.00
53.81% Upside
+0.0%
IONS
Ionis Pharmaceuticals
May 15, 2026 BUY Strong Buy
+13.3% avg upside
43 analysts
$115.00
55.25% Upside
-1.3%
ALT
Altimmune
May 14, 2026 BUY Strong Buy
+935.8% avg upside
19 analysts
$20.00
640.76% Upside
-0.7%
SRPT
Sarepta Therapeutics
May 12, 2026 HOLD Buy
+244.5% avg upside
49 analysts
$20.00
14.13% Upside
-17.7%
ASND
Ascendis Pharma
May 11, 2026 BUY Strong Buy
+17.0% avg upside
24 analysts
$345.00
49.54% Upside
-3.1%
MDGL
Madrigal Pharmaceuticals
May 08, 2026 BUY Strong Buy
-5.8% avg upside
31 analysts
$964.00
90.57% Upside
-0.8%
VRTX
Vertex Pharmaceuticals
May 06, 2026 BUY Strong Buy
-2.6% avg upside
61 analysts
$615.00
36.17% Upside
+7.3%
ALNY
Alnylam Pharma
May 06, 2026 BUY Strong Buy
+23.6% avg upside
51 analysts
$527.00
89.47% Upside
-6.7%
RARE
Ultragenyx Pharmaceutical
May 06, 2026 BUY Strong Buy
+142.1% avg upside
36 analysts
$43.00
56.70% Upside
-10.9%
KYMR
Kymera Therapeutics
May 01, 2026 BUY Strong Buy
+8.9% avg upside
36 analysts
$133.00
46.99% Upside
+11.4%
SGMT
Sagimet Biosciences, Inc. Class A
Apr 02, 2026 HOLD Strong Buy
+317.2% avg upside
15 analysts
$8.00
19.86% Upside
+29.7%
FDMT
4D Molecular Therapeutics
Jan 27, 2026 BUY Strong Buy
+265.1% avg upside
15 analysts
$33.00
241.71% Upside
+7.8%
BNTX
BioNTech SE
Nov 06, 2025 HOLD Strong Buy
+50.5% avg upside
26 analysts
$117.00
28.82% Upside
-12.1%
ANAB
AnaptysBio
Aug 12, 2025 HOLD Strong Buy
+26.1% avg upside
26 analysts
$20.00
65.13% Downside
+329.7%
GILD
Gilead Sciences
Aug 08, 2025 HOLD Strong Buy
-4.8% avg upside
66 analysts
$112.00
9.52% Downside
+6.3%
ARWR
Arrowhead Pharmaceuticals
Jul 21, 2025 HOLD Strong Buy
-19.2% avg upside
26 analysts
$12.00
85.31% Downside
+406.6%
PROK
ProKidney
Jul 15, 2025 BUY Buy
+260.7% avg upside
12 analysts
$8.00
337.17% Upside
-46.0%
ARVN
Arvinas Holding Company
May 15, 2025 BUY Strong Buy
+264.5% avg upside
27 analysts
$21.00
173.77% Upside
+45.1%
ZNTL
Zentalis Pharmaceuticals
Jan 28, 2025 HOLD Buy
+292.3% avg upside
16 analysts
$2.20
40.52% Downside
+6.7%
RVMD
Revolution Medicines
Jan 08, 2025 BUY Strong Buy
-12.3% avg upside
32 analysts
$71.00
56.47% Downside
+141.8%
KOD
Kodiak Sciences
Apr 04, 2024 HOLD Buy
+37.3% avg upside
11 analysts
$5.00
86.14% Downside
-42.4%
GLUE
Monte Rosa Therapeutics
Oct 13, 2022 BUY Strong Buy
+27.5% avg upside
14 analysts
$22.00
20.21% Upside
-38.6%
RNAC
Cartesian Therapeutics
Mar 03, 2021 BUY Strong Buy
+228.2% avg upside
19 analysts
$10.00
3.84% Upside
-57.2%
LKFT
Lakefront Biotherapeutics
Aug 19, 2020 HOLD Buy
+272.4% avg upside
24 analysts
$134.00
373.59% Upside
·
PRQR
ProQR
Dec 11, 2019 BUY Strong Buy
+516.3% avg upside
18 analysts
$40.00
2016.43% Upside
-51.1%
WHWK
Whitehawk Therapeutics
Mar 18, 2019 BUY Buy
+201.4% avg upside
12 analysts
$8.00
81.06% Upside
-63.1%
🔒 32 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Eliana Merle — Frequently Asked Questions
How accurate are Eliana Merle's stock ratings?
Based on the calls 13Foresight could measure, about 51% of Eliana's ratings were profitable over a one-year hold, with an average return of +33.3% per rating, or +25.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Eliana ranked on 13Foresight?
Eliana Merle is currently ranked #950 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Eliana cover?
Eliana most recently has ratings on QURE, MBX, BBIO, IVA, TYRA, MRNA, INSM, PTCT, BMRN, GOSS, REGN, RGNX and 25 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.